U.S. Online Retail and Ecommerce Stock News

Old National Bancorp (ONB) recently increased its quarterly common stock dividend by 3.6% to $0.145 per share, a move that can draw income focused investors’ attention to how the stock currently trades. See our latest analysis for Old National Bancorp. Old National Bancorp’s latest dividend increase comes as the share price has been under short term pressure, with a 7 day share price return of 4.27% decline and a 30 day share price return of 5.44% decline. However, the 90 day share price...

Coca-Cola (KO) just approved its 64th consecutive annual dividend increase, lifting the quarterly payout by about 4% to $0.53 per share. This move directly targets income focused investors. See our latest analysis for Coca-Cola. At a share price of $81.56, Coca-Cola’s recent 30-day share price return of 9.02% and year to date gain of 18.00% suggest building momentum. The 5-year total shareholder return of 83.58% points to solid longer term compounding alongside the latest dividend increase...

In February 2026, Intapp launched Intapp Celeste, a purpose-built agentic AI platform for professional firms, while expanding AI collaborations with Harvey and Anthropic’s Claude to embed governed, workflow-specific AI across its portfolio. This marks a shift toward AI agents acting as expert colleagues inside highly regulated workflows, enforcing ethical walls, handling sensitive data, and integrating deeply with tools like DealCloud, Microsoft 365, and Claude. We’ll explore how Intapp’s...

If you are wondering whether Upwork's recent share price swings have created an opportunity or a value trap, looking closely at what the market is actually pricing in can help frame your next move. Upwork's shares last closed at US$13.42, with a 7 day return of 7.3%, a 30 day return of a 33.0% decline, a year to date return of a 32.4% decline, a 1 year return of an 8.8% decline, a 3 year return of 12.5% and a 5 year return of a 68.2% decline. Recent attention on Upwork has centered on how...

If you are wondering whether Day One Biopharmaceuticals' current share price lines up with its underlying worth, you are not alone. The stock most recently closed at US$10.60, with a 7 day return of 10% decline, a 30 day return of 5% decline, gains of 19.8% year to date and 17% over the past year, while the 3 year return sits at 43.4% decline. Recent news around Day One has largely focused on its development stage oncology pipeline and ongoing progress in clinical programs, which can...

If you are wondering whether PPL's share price still lines up with its underlying value, you are not alone. This article focuses on what the current price might be implying. PPL shares recently closed at US$38.98, with returns of 4.1% over 7 days, 7.5% over 30 days, 11.0% year to date and 14.3% over 1 year, while the 3 and 5 year returns sit at 57.8% and 67.2% respectively. Recent coverage around PPL has broadened investor attention to its role in the US utilities sector and how the company...

Provident Financial Services recently reported fourth-quarter 2025 earnings that surpassed analyst expectations and highlighted a solid financial foundation, while director Robert E. McCracken sold 6,177 shares for US$136,697 and Provident Bank appointed Joseph A. Tammaro Jr. as executive vice president and head of middle market lending. Together, the earnings beat, insider transaction, and leadership hire in middle market banking give investors fresh information on profitability,...

Ameren Corporation recently completed several fixed‑income transactions, including a US$399.21 million offering of 5% senior notes due 2036, alongside earlier first mortgage bond issuances by Ameren Missouri to refinance short‑term debt and support grid investments. Together, these bond deals reshape Ameren’s funding mix by locking in long‑term, fixed‑rate capital and reducing refinancing uncertainty around its large infrastructure program. Next, we’ll explore how Ameren’s shift toward...

Westlake Corporation has reported weaker results for the fourth quarter and full year 2025, with sales falling to US$2,533 million and a quarterly net loss of US$544 million, alongside the planned retirement of long-serving Chief Financial Officer M. Steven Bender and the appointment of Bhavesh V. “Bob” Patel and CEO Jean-Marc Gilson to an expanded Board. Despite these earnings pressures and leadership changes, the Board’s decision to maintain a regular US$0.53 per-share dividend and the...

Apollo Global Management has recently faced pressure after Apollo-managed MidCap Financial Investment Corp. cut its dividend and marked down older assets, while a law firm began investigating potential securities issues tied to past executive discussions about tax arrangements with Jeffrey Epstein. These developments, alongside rising investor focus on credit quality in private-credit funds, have amplified concerns about how resilient Apollo’s broader platform may be to shifts in risk...

Werner Enterprises stock: event context and recent performance snapshot Werner Enterprises (WERN) has drawn investor attention after its latest reported annual results, which showed revenue of US$2.97b and a net loss of US$14.40m, alongside mixed share performance across the past year. See our latest analysis for Werner Enterprises. At a share price of US$35.09, Werner’s recent 90 day share price return of 29.10% and year to date gain of 14.64% point to building momentum. However, the 3 year...

VisionWave Holdings, Inc. recently signed a Memorandum of Understanding with a German aerospace systems provider and an Israeli interceptor drone developer to explore non-explosive interceptor drone solutions for the Bundeswehr and other German government entities, aligned with NATO-related rules-of-engagement and regulatory constraints. This early-stage cooperation highlights growing interest in alternative, non-explosive interception methods that seek to meet strict European defense...

Edwards Lifesciences recently secured U.S. FDA approval for its SAPIEN M3 transcatheter mitral valve replacement system, issued 2026 sales guidance, and saw an FTC injunction block its planned JenaValve acquisition, while an EU antitrust investigation into its policies concluded. These developments collectively reduce legal uncertainty, highlight Edwards’ innovation in structural heart therapies, and align with its goal to broaden global access to cardiovascular treatments by 2030. We’ll now...

Recent share performance and business snapshot J. M. Smucker (SJM) has drawn investor attention after a period of steady gains, with the stock showing positive returns over the past week, month, past 3 months, year to date, and past year. The food and beverage group, which owns brands such as Folgers, Café Bustelo, Dunkin’, Jif, Smucker’s, Meow Mix, Milk-Bone and Hostess, now trades around $115.95 and reports annual revenue of about $8.9b. See our latest analysis for J. M. Smucker. The recent...

PureCycle Technologies (PCT) has drawn fresh investor attention after reporting record fourth quarter production of PureFive recycled polypropylene, advancing its Thailand and Antwerp projects, and outlining a planned CFO transition. See our latest analysis for PureCycle Technologies. Despite record PureFive production and new partnerships, PureCycle’s recent price action has been weak, with a 1 month share price return of a 34% decline and a 1 year total shareholder return of a 38.74%...

What the latest earnings tell you about Diversified Healthcare Trust Diversified Healthcare Trust (DHC) has just reported fourth quarter and full year 2025 results, showing lower quarterly sales but a narrower net loss, a combination that naturally puts the stock back on investors’ radar. See our latest analysis for Diversified Healthcare Trust. That earnings update landed after a strong run in the shares, with a 90 day share price return of 39.96% and a year to date share price return of...

Mercury Systems (MRCY) recently reported year over year growth in bookings, revenue, adjusted EBITDA, and backlog, supported by faster customer deliveries and factory automation investments, and outlined new opportunities linked to the defense budget. See our latest analysis for Mercury Systems. At a share price of US$89.03, Mercury Systems has seen a 33.28% 90 day share price return and a very large 100.47% 1 year total shareholder return, suggesting recent momentum has been strong as...

Murphy USA (MUSA) has drawn fresh attention after a cluster of insider stock sales by senior leaders, including its fuels chief and a board director, following recent mixed analyst commentary on the retailer’s latest quarterly update. See our latest analysis for Murphy USA. The recent insider selling comes as Murphy USA’s share price, at US$390.74, shows mixed momentum, with a 30 day share price return of a 7.5% decline, a 3 year total shareholder return of 51.96% and a 5 year total...

What the new shelf registration could mean for Blue Owl Capital Blue Owl Capital (OWL) recently filed a US$615.5 million shelf registration for up to 50,000,000 Class A shares tied to an ESOP related offering, adding a fresh wrinkle to its income focused story. This move arrives alongside management’s commitment to a fixed US$0.92 annual dividend for 2026 and strong demand for its private wealth products, including a 66% year over year increase in dedicated offerings targeting individual...

Bentley Systems (BSY) is back on investors’ radar after its fourth quarter and full year 2025 results beat revenue expectations, and management issued 2026 guidance that came in above prior analyst forecasts. See our latest analysis for Bentley Systems. Even after a strong post earnings bounce, Bentley Systems’ latest share price of US$36.55 still reflects a 12.7% 90 day share price decline and a 16.2% 1 year total shareholder return decline. As a result, the recent 8% 7 day share price gain...

MannKind (MNKD) is back in focus after partner United Therapeutics introduced a soft mist inhaler designed to compete with Tyvaso DPI, raising fresh questions around MannKind’s future royalty stream and overall risk profile. See our latest analysis for MannKind. The stock’s 7 day share price return of 40.79% and 30 day share price return of 43.25% follow earnings that paired higher revenue with a quarterly loss, while the United Therapeutics soft mist inhaler news sharply reset sentiment...

Vera Therapeutics (VERA) is back in focus after the FDA granted priority review to its lead drug candidate, atacicept, following positive Phase 3 IgA nephropathy data and company updates on funding and launch readiness. See our latest analysis for Vera Therapeutics. Despite the FDA priority review and Phase 3 success for atacicept, Vera Therapeutics’ recent share price returns have cooled, with a 30 day share price return decline of 5.71% and a year to date share price return decline of...

In late February 2026, Pinnacle Financial Partners was highlighted by hedge funds as one of the ten leading banking stocks, with analysts citing stronger capital levels and higher earnings forecasts following its fourth-quarter results and management’s confident outlook. A few days later, hotter-than-expected inflation data and rising worries about credit risk in areas like private credit and leveraged loans led investors to reassess regional banks’ risk profiles, putting pressure on...

Shift4 Payments (FOUR) is back in focus after a sharp post earnings sell off, weaker forward guidance, and the resignation of Executive Chairman Jared Isaacman. Shares have slid to multi year lows despite ongoing international expansion. See our latest analysis for Shift4 Payments. The weak outlook and leadership change have come on top of a sharp reset in expectations, with a 1 day share price return of 9.0% decline and a 1 year total shareholder return of 55.4% decline, pointing to fading...